Advertisement

Topics

Latest "A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis" News Stories

02:58 EDT 23rd March 2019 | BioPortfolio

Here are the most relevant search results for "A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis" found in our extensive news archives from over 250 global news sources.

More Information about A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis for you to read. Along with our medical data and news we also list A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis Clinical Trials, which are updated daily. BioPortfolio also has a large database of A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis Companies for you to search.

Showing "Randomized Double Blind Protocol Comparing Amphotericin With Flucytosine" News Articles 1–25 of 2,700+

Friday 22nd March 2019

SeqOnce Biosciences Launches RhinoSeq™ Rapid DNA Library Preparation Kit

SeqOnce Biosciences Inc. launches its new RhinoSeq™ DNA Library Preparation Kit for Next Generation Sequencing (NGS) sample preparation. PASADENA, Calif. (PRWEB) March 22, 2019 SeqOnce Biosciences Inc. launches its new RhinoSeq™ DNA Library Preparation Kit for Next Generation Sequencing (NGS) sample preparation. RhinoSeq employs a proprietary kit chemistry that makes it the fastest DNA librar...


[Articles] Monthly sulfadoxine–pyrimethamine versus dihydroartemisinin–piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial

Monthly intermittent preventive treatment with dihydroartemisinin–piperaquine was safe but did not lead to significant improvements in birth outcomes compared with sulfadoxine–pyrimethamine.

[Articles] β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

Long-term treatment with β blockers could increase decompensation-free survival in patients with compensated cirrhosis and CSPH, mainly by reducing the incidence of ascites.


Radical Opioid Restriction Works for Postoperative Patients

An ultrarestrictive opioid prescription protocol radically reduces postoperative opioid use in patients with gynecological cancer who do not have compromising outcomes. Medscape Medical News

USAWorldMeds Names Neurologist & Addiction Medicine Specialist Dr. Russell Surasky as Expert Speaker for New Ground-Breaking Medication Lucemyra

Lucemyra is the First FDA Approved Medicine to Treat Opioid Withdrawal Syndrome (OWS). GREAT NECK. N.Y. (PRWEB) March 22, 2019 “Not a day goes by when we don’t learn more about the devastation caused by opioid addiction. Every day in the United States approximately 4,000 individuals start using opiates for non-medical purposes. We are now up to about 130 opioid overdoses per day,” says Neur...

$BIIB double downgraded to Underweight at MS. PT $210 from $401

$BIIB double downgraded to Underweight at MS. PT $210 from $401

AlzProtect Starts Collaboration with PAREXEL Biotech for Phase 2a of AZP2006 for the Treatment of Progressive Supranuclear Palsy (PSP)

LILLE, France, March 22, 2019 / B3C newswire / -- ALZPROTECT, a biopharmaceutical company engaged in the development of drugs for the treatment of Alzheimer's disease, today announced that PAREXEL Biotech, a new division of PAREXEL International Corporation, has been selected to perform the clinical phase 2a development of

Optimizing protocol design and enhancing patient enrollment

Using their extensive proprietary data sources, Covance guided an emerging pharmaceutical company who was uncertain about how to balance the selection of the right patients for their trial endpoints with the ability to achieve rapid patient recruiting.

Thursday 21st March 2019

Financial incentives didn't improve response rates to mailed colorectal cancer screening tests

(JAMA Network) Financial incentives didn't increase completion rates of colorectal cancer screening tests mailed to patients. In a randomized clinical trial of almost 900 patients, none of the incentives (an unconditional $10, a promised $10 upon completion of the fecal immunochemical test (FIT) kit to test for blood in a stool sample or chance at a lottery with a 1-in-10 chance of winning $100) w...

IMV Inc. Announces 2018 Year-end Financial and Operational Results and Provides Updates on Key Clinical Programs

Attained multiple milestones in DECIDE1/2 clinical program in advanced ovarian cancer Achieved initial positive data from phase 2 clinical trial in DLBCL with Merck Initiated a phase 2 basket trial across five indications under a collaboration with Merck Listed on Nasdaq and changed Corpora...

Developmental Screening and Care Coordination Through 2-1-1 Telephone Service

Families randomized to working with a 2-1-1 coordinator were more likely to receive developmental screening, referral and services.

Adlai Nortye Receives NMPA Approval for Pelareorep (AN1004) in China to Initiate Phase III Clinical Trials

HANGZHOU, China, March 21, 2019 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today announced that it has received a clearance from the National Medical Products Administration (NMPA) of China for initiating the open-label, randomized, multicenter, global phase III clinical trial for pelareorep (AN1004) in combination with pacl...

Poxel Reports Financial Results for Full Year 2018 and Provides Corporate Update

Executed strategic agreement for Imeglimin with Roivant Sciences; potential for up to USD 600 million in regulatory and development milestone payments and sales-based payments plus royalties on net sales Roivant concurrently invested USD 15 million (approximately EUR 12 million) in Poxel through subscription in newly-issued ordinary ...

Loose Dentures in Waterbury, CT, Secured with All-on-4® Full Arch Dental Implants by Drs. Richard Amato and Michael Kang

Dr. Richard Amato and Dr. Michael Kang welcome patients with missing teeth and/or loose dentures in Waterbury, CT for an All-on-4® full arch dental implants consultation. Drs. Amato and Kang practice periodontology and implantology in Monroe, CT, serving patients from Trumbull, Shelton, Danbury, Newtown, and Waterbury, CT. Waterbury, CT (PRWEB) March 21, 2019 Patients with missing teeth or t...

Dan Jeffries was diagnosed with ultra-rare Wyburn-Mason syndrome at a young age, leaving him blind in one eye. This was compounded when he found he was living with not one, but two rare conditions, complicating treatment and leading to some close calls h

Dan Jeffries was diagnosed with ultra-rare Wyburn-Mason syndrome at a young age, leaving him blind in one eye. This was compounded when he found he was living with not one, but two rare conditions, complicating treatment and leading to some close calls http://bit.ly/2HBAgay  pic.twitter.com/dROXn9qzsc

Intelligent Waves Awarded $2.9M Contract by the United States Department of Veterans Affairs

Intelligent Waves LLC, an end-to-end information technology solutions provider, today announced that it was awarded a $2.9 million task order to deliver information technology support to the Department of Veterans Affairs (VA). Enabling efficient and effective care of veterans, the task order – awarded under VA’s Transformation Twenty-One Total Technol...

PhotoOpTx Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Network

Diabetic macular edema (DME) is the most common condition that contributes to vision loss in persons with diabetes. PhotoOpTx, LLC has entered into an agreement with the Jaeb Center for Health Research Foundation acting on the behalf of the DRCR Network to provide devices for "A Pilot Study Evaluating Photobiomodulation Therapy for Diabetic Macular Edema". SOLON, Ohio (PRWEB) March 21, 2...

Biogen Shares Fall As Late-stage Trials Of Alzheimer's Drug Discontinued

Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab.

Robotic Surgery Market Expected to More than Double to $7 billion by 2025 – New Study by iData Research

Could your next surgery be done by a robot? With procedure volumes rising, there’s a good chance that this will be the case. Mirroring the quick-paced nature of new technological innovations, the surgical robotics market has experienced significant prosperity recently, which is expected to continue through 2025. Currently valued at over $3 billion, this ...

International recruitment needed to fix NHS staff shortages says new report

The King’s Fund think-tank has claimed that in the next five years nurse shortages will double and GP gaps could potentially nearly triple to 7,000.

ACC: Robust Evidence Lacking for Many Cardiovascular Guidelines

THURSDAY, March 21, 2019 -- Only a small proportion of recommendations in major cardiovascular society guidelines are supported by evidence from multiple randomized controlled trials (RCTs) or a single large RCT, according to a study published in...

ZipLine Medical Announces New Emergency Department Study Showing Significant Time and Cost Savings, and Superior Patient Satisfaction, with Laceration Closure Using Zip® Surgical Skin Closure

ZipLine Medical, Inc. today announced presentation of positive results from a randomized, prospective clinical study conducted at the Karolinska University Hospital in Stockholm, Sweden demonstrating both clinical and economic benefits of the Zip® Surgical Skin Closure device when used in an emergency medicine setting for lacerations. A poster...

Program Improves Communication Between Oncology Clinicians and Patients

The Serious Illness Care Program helps oncologists have better serious-illness conversations with patients without creating anxiety or depression, according to results of a cluster-randomized clinical trial. Reuters Health Information

FDA to assess double filing from Novo Nordisk

Danish pharma group awaits decision on oral diabetes drug and Ozempic

Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019

A special symposium session, intended to highlight therapeutic advances, will focus on Tumor Treating Fields as a fourth modality in cancer treatment The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference Novocure (NASDAQ: NVCR) announced today 48 presentations on Tumor Treat...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks